All posts by PIER MARIA FORNASARI

PIER MARIA FORNASARI
2022-01-18

Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain

Survivors of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection frequently experience lingering neurological symptoms, including impairment in attention, concentration, speed of information processing and memory. This long-COVID cognitive syndrome shares many features with the syndrome of cancer therapy-related cognitive impairment (CRCI). Neuroinflammation, particularly microglial reactivity and consequent dysregulation of hippocampal neurogenesis and oligodendrocyte lineage cells,

Read More

No Comments InUncategorized
PIER MARIA FORNASARI
2022-01-18

Association between vaccination status and reported incidence of post-acute long-COVID-19 symptoms in Israel: double dose Pfizer-BioNTech vaccination may have a protective effect.

An emerging and complex health problem that remains poorly characterized and understood is long coronavirus disease 2019 (Long COVID). The rapid outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic. Long COVID is a post-infection condition in which individuals do not recover completely for

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-01-16

Viral dynamics and duration of PCR positivity of the SARSCoV-2 Omicron variant: a study of Harvard University researchers on NBA players

A significant proportion of people infected with the omicron variant of coronavirus were still contagious when they reach the U.S. Centers for Disease Control’s recommended self-isolation exit date of five days, according to a  Harvard University study of a small number of cases from the National Basketball Association’s Covid-19 testing program. KEY FACTS Among omicron cases identified 

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-01-15

COVID-19 nonhospitalized patients: therapeutic options review in Omicron era

Substantial progress has been made in therapeutics for nonhospitalized patients with COVID-19, but supply of and access to treatment remain limited. This Viewpoint summarizes currently available therapeutics for nonhospitalized patients in the setting of the Omicron variant including principles for equitable allocation. Patients with mild or moderate COVID-19 are those who have respiratory and systemic

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-01-11

NIH researchers develop first stem cell model of albinism to study related eye conditions

A human induced pluripotent stem cell colony from OCA1A patient. The image was acquired using a confocal microscope and is stained for pluripotency marker proteins. The red color depicts transcription factor OCT4, green is SSEA4 protein and blue represents the nucleus of the cells.NEI “Animals used to study albinism are less than ideal because they

Read More

No Comments InRESEARCH
PIER MARIA FORNASARI
2022-01-11

Engineered Mesenchymal Stem Cells as a Biotherapy Platform for Targeted Photodynamic Immunotherapy of Breast Cancer

Interleukin-12 (IL12) is a pleiotropic cytokine with promising prospects for cancer immunotherapy. Though IL12 gene-based therapy could overcome the fatal hurdle of severe systemic toxicity, targeted delivery and tumor-located expression of IL12 gene remain the challenging issues yet to be solved. Photo-immunotherapy emerging as a novel and precise therapeutic strategy, which elaborately combines immune-activating agents

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2022-01-11

CAR-T-cell therapy has the potential to replace chemoimmunotherapy for second-line treatment of patients with refractory or relapsed large B-cell lymphoma (LBCL)

In the ZUMA-7 trial, at a median follow-up of 24.9 months, patients randomly assigned to receive CAR T-cell therapy with axicabtagene ciloleucel, or axi-cell (Yescarta) had a median event-free survival (EFS) of 8.3 months, compared with 2 months for patients randomly assigned to standard-of-care chemoimmunotherapy, reported Frederick L. Locke, MD, from the Moffitt Cancer Center

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-01-11

NEJM paper, compendium on rapid tests for COVID-19 published by University of Washington researcher

The FDA has approved 28 of the more than 1,000 such diagnostics commercially available worldwide. In brief: A clinical practice article in the New England Journal of Medicine distills available data and clinical experience into a compendium about rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The appendix identified nearly all FDA-approved rapid diagnostic tests and

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-01-11

Illinois College University researchers uncover new information about cellular death process, previously thought to be irreversible

A study published by researchers at the University of Illinois Chicago describes a new method for analyzing pyroptosis — the process of cell death that is usually caused by infections and results in excess inflammation in the body — and shows that process, long thought to be irreversible once initiated, can in fact be halted

Read More

No Comments InRESEARCH